Studies on left ventricular hypertrophy regression in arterial hypertension

A clear message for the clinician?

Cesare Cuspidi, Arturo Esposito, Francesca Negri, Carla Sala, Meilikè Masaidi, Valentina Giudici, Alberto Zanchetti, Giuseppe Mancia

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Evidence-based medicine should provide clear and unbiased information to clinicians. We conducted an analysis on published randomized trials evaluating the effects of antihypertensive therapy on left ventricular (LV) morphology assessed by echocardiography to investigate (i) the consistency of criteria used for definition of LV hypertrophy (LVH) and (ii) the consistency of the way LVH regression and blood pressure (BP) control were reported. Methods: Studies identified by a PubMed search were eligible for inclusion in the analysis, if they fulfilled the following criteria: (i) publication in a peer-reviewed journal within the last 12 years; (ii) double blind, randomized, controlled, parallel-group design; (iii) numerosity of at least 50 adult hypertensive subjects; (iv) follow-up duration of at least 6 months; (v) comparison between single-drugs or association regimens; (vi) LV mass (LVM) or wall thickness measured by echocardiography. Results: Thirty-nine trials, including 9,162 hypertensive subjects of both genders in 78 active treatment arms or in 6 placebo arms were identified. Definition of LVH was provided by 34 studies (87.1%) according to 19 different criteria. All trials evaluated LVH regression as the absolute or relative changes of continuous variables such as LVM index (LVMI) or LV wall thickness. Data concerning prevalence rates of LVM normalization were reported in 12 studies (30.7%). The percentage of patients reaching BP target (

Original languageEnglish
Pages (from-to)458-463
Number of pages6
JournalAmerican Journal of Hypertension
Volume21
Issue number4
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Left Ventricular Hypertrophy
Hypertrophy
Hypertension
Echocardiography
Blood Pressure
Evidence-Based Medicine
PubMed
Antihypertensive Agents
Publications
Placebos
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Studies on left ventricular hypertrophy regression in arterial hypertension : A clear message for the clinician? / Cuspidi, Cesare; Esposito, Arturo; Negri, Francesca; Sala, Carla; Masaidi, Meilikè; Giudici, Valentina; Zanchetti, Alberto; Mancia, Giuseppe.

In: American Journal of Hypertension, Vol. 21, No. 4, 04.2008, p. 458-463.

Research output: Contribution to journalArticle

Cuspidi, Cesare ; Esposito, Arturo ; Negri, Francesca ; Sala, Carla ; Masaidi, Meilikè ; Giudici, Valentina ; Zanchetti, Alberto ; Mancia, Giuseppe. / Studies on left ventricular hypertrophy regression in arterial hypertension : A clear message for the clinician?. In: American Journal of Hypertension. 2008 ; Vol. 21, No. 4. pp. 458-463.
@article{7ae8c9948a0f431bad4c0ee5d889a9c6,
title = "Studies on left ventricular hypertrophy regression in arterial hypertension: A clear message for the clinician?",
abstract = "Background: Evidence-based medicine should provide clear and unbiased information to clinicians. We conducted an analysis on published randomized trials evaluating the effects of antihypertensive therapy on left ventricular (LV) morphology assessed by echocardiography to investigate (i) the consistency of criteria used for definition of LV hypertrophy (LVH) and (ii) the consistency of the way LVH regression and blood pressure (BP) control were reported. Methods: Studies identified by a PubMed search were eligible for inclusion in the analysis, if they fulfilled the following criteria: (i) publication in a peer-reviewed journal within the last 12 years; (ii) double blind, randomized, controlled, parallel-group design; (iii) numerosity of at least 50 adult hypertensive subjects; (iv) follow-up duration of at least 6 months; (v) comparison between single-drugs or association regimens; (vi) LV mass (LVM) or wall thickness measured by echocardiography. Results: Thirty-nine trials, including 9,162 hypertensive subjects of both genders in 78 active treatment arms or in 6 placebo arms were identified. Definition of LVH was provided by 34 studies (87.1{\%}) according to 19 different criteria. All trials evaluated LVH regression as the absolute or relative changes of continuous variables such as LVM index (LVMI) or LV wall thickness. Data concerning prevalence rates of LVM normalization were reported in 12 studies (30.7{\%}). The percentage of patients reaching BP target (",
author = "Cesare Cuspidi and Arturo Esposito and Francesca Negri and Carla Sala and Meilik{\`e} Masaidi and Valentina Giudici and Alberto Zanchetti and Giuseppe Mancia",
year = "2008",
month = "4",
doi = "10.1038/ajh.2007.85",
language = "English",
volume = "21",
pages = "458--463",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Studies on left ventricular hypertrophy regression in arterial hypertension

T2 - A clear message for the clinician?

AU - Cuspidi, Cesare

AU - Esposito, Arturo

AU - Negri, Francesca

AU - Sala, Carla

AU - Masaidi, Meilikè

AU - Giudici, Valentina

AU - Zanchetti, Alberto

AU - Mancia, Giuseppe

PY - 2008/4

Y1 - 2008/4

N2 - Background: Evidence-based medicine should provide clear and unbiased information to clinicians. We conducted an analysis on published randomized trials evaluating the effects of antihypertensive therapy on left ventricular (LV) morphology assessed by echocardiography to investigate (i) the consistency of criteria used for definition of LV hypertrophy (LVH) and (ii) the consistency of the way LVH regression and blood pressure (BP) control were reported. Methods: Studies identified by a PubMed search were eligible for inclusion in the analysis, if they fulfilled the following criteria: (i) publication in a peer-reviewed journal within the last 12 years; (ii) double blind, randomized, controlled, parallel-group design; (iii) numerosity of at least 50 adult hypertensive subjects; (iv) follow-up duration of at least 6 months; (v) comparison between single-drugs or association regimens; (vi) LV mass (LVM) or wall thickness measured by echocardiography. Results: Thirty-nine trials, including 9,162 hypertensive subjects of both genders in 78 active treatment arms or in 6 placebo arms were identified. Definition of LVH was provided by 34 studies (87.1%) according to 19 different criteria. All trials evaluated LVH regression as the absolute or relative changes of continuous variables such as LVM index (LVMI) or LV wall thickness. Data concerning prevalence rates of LVM normalization were reported in 12 studies (30.7%). The percentage of patients reaching BP target (

AB - Background: Evidence-based medicine should provide clear and unbiased information to clinicians. We conducted an analysis on published randomized trials evaluating the effects of antihypertensive therapy on left ventricular (LV) morphology assessed by echocardiography to investigate (i) the consistency of criteria used for definition of LV hypertrophy (LVH) and (ii) the consistency of the way LVH regression and blood pressure (BP) control were reported. Methods: Studies identified by a PubMed search were eligible for inclusion in the analysis, if they fulfilled the following criteria: (i) publication in a peer-reviewed journal within the last 12 years; (ii) double blind, randomized, controlled, parallel-group design; (iii) numerosity of at least 50 adult hypertensive subjects; (iv) follow-up duration of at least 6 months; (v) comparison between single-drugs or association regimens; (vi) LV mass (LVM) or wall thickness measured by echocardiography. Results: Thirty-nine trials, including 9,162 hypertensive subjects of both genders in 78 active treatment arms or in 6 placebo arms were identified. Definition of LVH was provided by 34 studies (87.1%) according to 19 different criteria. All trials evaluated LVH regression as the absolute or relative changes of continuous variables such as LVM index (LVMI) or LV wall thickness. Data concerning prevalence rates of LVM normalization were reported in 12 studies (30.7%). The percentage of patients reaching BP target (

UR - http://www.scopus.com/inward/record.url?scp=41349093821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41349093821&partnerID=8YFLogxK

U2 - 10.1038/ajh.2007.85

DO - 10.1038/ajh.2007.85

M3 - Article

VL - 21

SP - 458

EP - 463

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 4

ER -